Cited by 165Endometriosis Research and TreatmentGynecological conditions and treatmentsUterine Myomas and Treatments

The DOI matches its Crossref record; 108 of the 116 references it cites were found in a registry or an index; 5 of the 89 sources its claims cite were checked for support.

The Pathogenesis of Adenomyosis vis-à-vis Endometriosis

Open access
Guo, Sun-Wei·2020·Journal of Clinical Medicine

Abstract

Adenomyosis is used to be called endometriosis interna, and deep endometriosis is now called adenomyosis externa. Thus, there is a question as to whether adenomyosis is simply endometriosis of the uterus, either from the perspective of pathogenesis or pathophysiology. In this manuscript, a comprehensive review was performed with a literature search using PubMed for all publications in English, related to adenomyosis and endometriosis, from inception to June 20, 2019. In addition, two prevailing theories, i.e., invagination—based on tissue injury and repair (TIAR) hypothesis—and metaplasia, on adenomyosis pathogenesis, are briefly overviewed and then critically scrutinized. Both theories have apparent limitations, i.e., difficulty in falsification, explaining existing data, and making useful predictions. Based on the current understanding of wound healing, a new hypothesis, called endometrial-myometrial interface disruption (EMID), is proposed to account for adenomyosis resulting from iatrogenic trauma to EMI. The EMID hypothesis not only highlights the more salient feature, i.e., hypoxia, at the wounding site, but also incorporates epithelial mesenchymal transition, recruitment of bone-marrow-derived stem cells, and enhanced survival and dissemination of endometrial cells dispersed and displaced due to iatrogenic procedures. More importantly, the EMID hypothesis predicts that the risk of adenomyosis can be reduced if certain perioperative interventions are performed. Consequently, from a pathogenic standpoint, adenomyosis is not simply endometriosis of the uterus, and, as such, may call for interventional procedures that are somewhat different from those for endometriosis to achieve the best results.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This review argues that adenomyosis is not simply endometriosis of the uterus, because the two conditions have different risk profiles, age-specific incidence, and likely pathogenesis. It critiques the invagination/TIAR and metaplasia theories and proposes the endometrial–myometrial interface disruption (EMID) hypothesis, centered on iatrogenic trauma, hypoxia, EMT, and bone-marrow-derived stem cell recruitment.

Key findings

  • Reported adenomyosis prevalence varies widely, from 10% to 57%; in a population-based study in Northeast Italy, estimated prevalence was 0.18% for adenomyosis versus 1.14% for endometriosis, with adenomyosis incidence peaking at ages 46–50 years.
  • Parity is consistently a risk factor for adenomyosis, smoking is inconsistently protective, and a history of dilatation and curettage (D&C) is suggested as a risk factor; this risk profile differs from endometriosis, where greater parity is protective and earlier menarche/shorter menstrual cycles are risk factors.
  • The review criticizes both prevailing adenomyosis theories—invagination/TIAR and metaplasia—as difficult to falsify, unable to fully explain existing data, and limited in making useful predictions; it notes the TIAR feed-forward loop is based almost exclusively on endometriotic stromal cells, whereas normal endometrial stromal cells have hypermethylated/silenced aromatase, SF-1, and ERβ.
  • The proposed EMID hypothesis holds that iatrogenic trauma to the endometrial–myometrial interface causes hypoxia, platelet aggregation, increased estrogen production, TGF-β1/VEGF/PDGF/COX-2/SDF-1 signaling, elevated PGE2, EMT, bone-marrow-derived stem cell recruitment, and impaired cell-mediated immunity, promoting survival and myometrial implantation of displaced endometrial cells; it predicts perioperative interventions may reduce adenomyosis risk.

Methods

  • Comprehensive review with a PubMed literature search for all English publications related to adenomyosis and endometriosis from inception to June 20, 2019.
  • Briefly overviews and critically scrutinizes the two prevailing adenomyosis pathogenesis theories—invagination/TIAR and metaplasia—then proposes the EMID hypothesis based on current understanding of wound healing.
  • No primary experimental data are reported in this review; it mentions that EMID can robustly induce adenomyosis in mice (Hao et al., submitted for publication) as cited/unpublished evidence.

Limitations

  • The paper states the EMID hypothesis may account for adenomyosis arising from iatrogenic trauma and perhaps persistent hyperperistalsis-induced EMID, but probably not focal adenomyosis of the outer myometrium (FAOM) or extrinsic/exterior adenomyosis.
  • The paper states the model is by no means final or complete and is subject to change or modification; other aiders and abettors may yet be identified, and upstream cues or risk factors for hyperperistalsis-induced EMID need elucidation.
  • Evident from the text: as a narrative review, it does not report a systematic review protocol, risk-of-bias assessment, or meta-analysis, and the mouse induction evidence is cited as submitted/unpublished rather than detailed in the paper.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/jcm9020485

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The key molecular signaling events initiated by the tissue injury and repair (TIAR) that leads to the increased local production of estradiol, as proposed by Leyendecker et al. [29,30]. Gene/protein names: COX-2: cyclooxygenase-2; E2: 17β-estradial; ERβ: estrogen receptor β; IL-1β: interleukin-1β; P450 aromatase: aromatase; PGE2: prostaglandin E2; StAR: steroidogenic acute regulatory protein.
Figure 1 The key molecular signaling events initiated by the tissue injury and repair (TIAR) that leads to the increased local production of estradiol, as proposed by Leyendecker et al. [29,30]. Gene/protein names: COX-2: cyclooxygenase-2; E2: 17β-estradial; ERβ: estrogen receptor β; IL-1β: interleukin-1β; P450 aromatase: aromatase; PGE2: prostaglandin E2; StAR: steroidogenic acute regulatory protein.CC BY · PubMed Central
Figure 2 Leyendecker’s model of tissue injury and repair (TIAR) that initiates the genesis of adenomyotic lesions [29,30]. Briefly, microtraumatization in the endometrial–myometrial interface causes tissue injury, which subsequently induces upregulation of COX-2 and increased production of PGE2, which, in turn, induces the expression of genes critical to estrogen production such as StAR and aromatase, resulting in increased local estrogen production. The elevated estrogen levels would activate both ERα and ERβ, leading to the induction of the OT/OTR signaling and subsequent increased uterine peristalsis and increased angiogenesis and proliferation. The increased peristalsis would further exacerbate uterine hyperperistalsis and thus TIAR, causing endometrial invagination and ultimately the formation of adenomyotic lesions. Gene/protein names: COX-2: cyclooxygenase-2; E2: 17β-estradial; ERα: estrogen receptor α; ERβ: estrogen receptor β; IL-1β: interleukin-1β; P450 aromatase: aromatase; OT: oxytocin; OTR: oxytocin receptor; PGE2: prostaglandin E2; StAR: steroidogenic acute regulatory protein.
Figure 2 Leyendecker’s model of tissue injury and repair (TIAR) that initiates the genesis of adenomyotic lesions [29,30]. Briefly, microtraumatization in the endometrial–myometrial interface causes tissue injury, which subsequently induces upregulation of COX-2 and increased production of PGE2, which, in turn, induces the expression of genes critical to estrogen production such as StAR and aromatase, resulting in increased local estrogen production. The elevated estrogen levels would activate both ERα and ERβ, leading to the induction of the OT/OTR signaling and subsequent increased uterine peristalsis and increased angiogenesis and proliferation. The increased peristalsis would further exacerbate uterine hyperperistalsis and thus TIAR, causing endometrial invagination and ultimately the formation of adenomyotic lesions. Gene/protein names: COX-2: cyclooxygenase-2; E2: 17β-estradial; ERα: estrogen receptor α; ERβ: estrogen receptor β; IL-1β: interleukin-1β; P450 aromatase: aromatase; OT: oxytocin; OTR: oxytocin receptor; PGE2: prostaglandin E2; StAR: steroidogenic acute regulatory protein.CC BY · PubMed Central
Figure 3 Schematic illustration of the formation of adenomyotic lesions due to the endometrial–myometrial interface disruption (EMID). Iatrogenic procedures causes disruption at the endometrial–myometrial interface (EMI), which leads to platelet aggregation and the induction of HIF-1α, effectively causing tissue hypoxia. Uterine hyperperistalsis may also induce EMI disruption (shown in dashed arrow). As a result, genes involved in estrogen production are upregulated, resulting in increased local production of estrogen and subsequent induction of both ERα and ERβ, which, in turn, leads to the induction of the OT/OTR signaling and increased uterine peristalsis. In addition, tissue hypoxia activates TGF-β1, VEGF, PDGF, COX-2, and SDF-1 signaling pathways, leading to increased angiogenesis, vascularature, and the recruitment of BMDSCs to the wounding site. The induction of COX-2 would also increase the production of PGH2 and TXA2, which also enhances uterine peristalsis. Moreover, the TGF-β1 signaling pathway induces EMT, leading to the invasion of endometrial epithelial cells to the EMI and further down to the myometrium. Tissue injury also would activate the HPA axis, leading to the release of catecholamines and PGE2, which collectively result in impaired cell-mediated immunity and, as such, enhances the survival of displaced and dispersed endometrial cells within the myometrium. All these events ultimately lead to the formation of adenomyotic lesions in the myometrium. Abbreviations used: BMDSC: bone marrow derived stem cells; COX-2: cyclooxygenase-2; E2: 17β-estradial; EMI: endometrial-myometrial interface; EMT: epithelial-mesenchymal transition; ERα: estrogen receptor α; ERβ: estrogen receptor β; HIF-1α: hypoxia-inducible factor 1α; HPA: hypothalamic-pituitary-adrenal; P450 aromatase: aromatase; PDGF: platelet-derived growth factor; OT: oxytocin; OTR: oxytocin receptor; PGE2: prostaglandin E2; PGH2: prostaglandin H2; SDF-1: stromal cell-derived factor 1; SF-1: steroidogenic factor-1; StAR: steroidogenic acute regulatory protein; TGF-β1: transforming growth factor β1; TXA2: thromboxane A2; VEGF: vascular endothelial growth factor.
Figure 3 Schematic illustration of the formation of adenomyotic lesions due to the endometrial–myometrial interface disruption (EMID). Iatrogenic procedures causes disruption at the endometrial–myometrial interface (EMI), which leads to platelet aggregation and the induction of HIF-1α, effectively causing tissue hypoxia. Uterine hyperperistalsis may also induce EMI disruption (shown in dashed arrow). As a result, genes involved in estrogen production are upregulated, resulting in increased local production of estrogen and subsequent induction of both ERα and ERβ, which, in turn, leads to the induction of the OT/OTR signaling and increased uterine peristalsis. In addition, tissue hypoxia activates TGF-β1, VEGF, PDGF, COX-2, and SDF-1 signaling pathways, leading to increased angiogenesis, vascularature, and the recruitment of BMDSCs to the wounding site. The induction of COX-2 would also increase the production of PGH2 and TXA2, which also enhances uterine peristalsis. Moreover, the TGF-β1 signaling pathway induces EMT, leading to the invasion of endometrial epithelial cells to the EMI and further down to the myometrium. Tissue injury also would activate the HPA axis, leading to the release of catecholamines and PGE2, which collectively result in impaired cell-mediated immunity and, as such, enhances the survival of displaced and dispersed endometrial cells within the myometrium. All these events ultimately lead to the formation of adenomyotic lesions in the myometrium. Abbreviations used: BMDSC: bone marrow derived stem cells; COX-2: cyclooxygenase-2; E2: 17β-estradial; EMI: endometrial-myometrial interface; EMT: epithelial-mesenchymal transition; ERα: estrogen receptor α; ERβ: estrogen receptor β; HIF-1α: hypoxia-inducible factor 1α; HPA: hypothalamic-pituitary-adrenal; P450 aromatase: aromatase; PDGF: platelet-derived growth factor; OT: oxytocin; OTR: oxytocin receptor; PGE2: prostaglandin E2; PGH2: prostaglandin H2; SDF-1: stromal cell-derived factor 1; SF-1: steroidogenic factor-1; StAR: steroidogenic acute regulatory protein; TGF-β1: transforming growth factor β1; TXA2: thromboxane A2; VEGF: vascular endothelial growth factor.CC BY · PubMed Central

Verification

Claims the paper makes

49 Not checked yet · 42 Own interpretation · 3 Partly supported · 3 No basis given · accuracy not yet measured

Verify all 84 references — free account

Show all 55 claims

  • It may state two separate claims as one. 31
  • Probably not a substantial claim. 15
42 of 42
  • The paper relies on this without support.

    The molecular mechanisms of wound healing in non-endometrial tissues apply to the endometrial–myometrial interface and adenomyosis pathogenesis.

    “Based on the current understanding of wound healing, a new hypothesis, called endometrial-myometrial interface disruption (EMID), is proposed to account for adenomyosis resulting from iatrogenic trauma to EMI.”
  • The paper relies on this without support.

    The mouse EMID model is a valid model for human adenomyosis.

    “In fact, EMID can robustly induce adenomyosis in mice (Hao et al., submitted for publication).”
  • The paper relies on this without support.

    Normal endometrial stromal cells studied in vitro reflect normal endometrial stromal cells in vivo.

    “Yet normal endometrial stromal cells are very different in behavior from endometriotic or even adenomyotic stromal cells.”
  • The paper relies on this without support.

    Iatrogenic procedures are common in gynecological practice nowadays.

    “iatrogenic procedures aplenty nowadays in gynecological practice”
  • The paper relies on this without support.

    Many medications used primarily for treating endometriosis can and have been used also for treating adenomyosis.

    “many medications used primarily for treating endometriosis can and have been used also for treating adenomyosis”
5 of 5

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. Lacassagne, 1935, Modifications progressive de I’uterus de la souris sous l’action prolongee de I’oestrone, C R Seances Soc. Bioi., 35, 320

Cited by

Sorted by citations

See all 165

Metadata

Authors
Guo, S.-W.
Affiliations
Fudan University (CN)
Corresponding author
Guo, Sun-Wei
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2020-02-10
Volume
9
Issue
2
Pages
485
ISSN
2077-0383 (ISSN-L)
OpenAlex
W3005308188
Cited by
165
References
116
Citations by year
2026: 26 · 2025: 18 · 2024: 30 · 2023: 22 · 2022: 32 · 2021: 28 · 2020: 8
FWCI
3.33
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Natural Science Foundation of China (81530040, 81771553)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
  • Health Sciences › Medicine › Obstetrics and Gynecology › Uterine Myomas and Treatments
Keywords
adenomyosis, endometriosis, wound healing, hypoxia, epithelial-mesenchymal transition, bone marrow-derived stem cells, iatrogenic injury, perioperative interventions, deep infiltrating endometriosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review